Bone Therapeutics heads for worst day ever on trial failure

Biosenic SA

30/08/2021 08:44

** Shares in Bone Therapeutics  BOTHE.BR  slump more than
30% and are on track for their worst day on record as the
Belgian biotech co's knee osteoarthritis study missed endpoints
    ** No statistically significant difference in pain reduction
could be observed between any of the treatment, placebo and
comparator groups, the company says  urn:newsml:reuters.com:*:nFWN2PZ041
    ** "These JTA-004 efficacy results are disappointing," CEO
says
    ** Bone Therapeutics has added it would consider the options
for the future of JTA-004 development in collaboration with
existing and potential partners

($1 = 0.8478 euros)

 (Reporting by Juliette Portala)
 ((juliette.portala@tr.com))